Bulletin
Investor Alert

Associated Press Archives | Email alerts

Sept. 24, 2020, 1:42 a.m. EDT

As Trump continues to press for coronavirus vaccine by Election Day, public health officials vow ‘no cutting corners’

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Pfizer Inc. (PFE)
  • X
    Johnson & Johnson (JNJ)
  • X
    Moderna Inc. (MRNA)

or Cancel Already have a watchlist? Log In

By Associated Press


Associated Press
Stephen Hahn, commissioner of the U.S. Food and Drug Administration, testifies Wednesday at a Senate Health, Education, Labor and Pensions Committee Hearing on the federal response to COVID-19.

WASHINGTON (AP) — A huge international study of a COVID-19 vaccine that aims to work with just one dose is getting underway as top U.S. health officials sought Wednesday to assure a skeptical Congress and public that they can trust any shots the government ultimately approves.

Hopes are high that answers about at least one of several candidates being tested in the U.S. could come by year’s end.

‘President Trump is still trying to sabotage the work of our scientists and public health experts for his own political ends.’

Sen. Patty Murray

“We feel cautiously optimistic that we will be able to have a safe and effective vaccine, although there is never a guarantee of that,” Dr. Anthony Fauci, infectious-diseases chief at the National Institutes of Health, told a Senate committee.

See: Just 4 in 10 Americans now say they would get the first coronavirus vaccine — and most don’t expect to pay out of pocket

President Donald Trump is pushing for a faster timeline, which many experts say is risky and may not allow for adequate testing. On Wednesday he tweeted a link to news about the new Johnson & Johnson vaccine study and said the Food and Drug Administration “must move quickly!”

See: Trump suggests he wouldn’t permit FDA to tighten standards for an emergency-use authorization of a coronavirus vaccine

“President Trump is still trying to sabotage the work of our scientists and public health experts for his own political ends,” Sen. Patty Murray, a Democrat from Washington state, said before ticking off examples of pressure on the FDA.

FDA Commissioner Stephen Hahn pledged that career scientists, not politicians, will decide whether any coronavirus vaccine meets clearly stated standards that it works and is safe. Vaccine development usually takes years but scientists have been racing to shorten that time, in part by manufacturing doses that will have to be thrown away if studies find they don’t work.

“Science will guide our decisions. FDA will not permit any pressure from anyone to change that,” Hahn said. “I will put the interest of the American people above anything else.”

FDA has faced criticism for allowing emergency use of some COVID-19 treatments backed by little evidence, but Hahn said if vaccine makers want that faster path to market, additional standards will be coming soon. Vaccines, unlike therapies, are given to healthy people and thus usually require more proof.

But Trump made clear at a Wednesday evening White House news conference that he was skeptical of any regulatory changes that might delay a vaccine’s authorization, even if those changes are aimed at increasing public trust. Asked about the FDA considering stricter guidelines for emergency approval, Trump suggested the effort was politically-motivated.

“I think that was a political move more than anything else,” he said, arguing that that the companies testing the vaccines, such as Pfizer /zigman2/quotes/202877789/composite PFE -1.29% , Johnson & Johnson /zigman2/quotes/201724570/composite JNJ -0.57%  and Moderna /zigman2/quotes/205619834/composite MRNA +0.61% , are capable of determining whether they work. “I have tremendous trust in these massive companies,” he said.

A handful of vaccines already are in final testing in the U.S. and other countries. In one of the largest studies yet, Johnson & Johnson aims to enroll 60,000 volunteers to test its single-dose approach in the U.S., South Africa, Argentina, Brazil, Chile, Colombia, Mexico and Peru. Other candidates in the U.S. require two shots.

J&J’s vaccine is made with slightly different technology than others in late-stage testing, modeled on an Ebola vaccine the company created.

/zigman2/quotes/202877789/composite
US : U.S.: NYSE
$ 37.43
-0.49 -1.29%
Volume: 34.96M
Oct. 27, 2020 4:04p
P/E Ratio
24.23
Dividend Yield
4.06%
Market Cap
$210.72 billion
Rev. per Employee
$580,595
loading...
/zigman2/quotes/201724570/composite
US : U.S.: NYSE
$ 143.15
-0.82 -0.57%
Volume: 4.89M
Oct. 27, 2020 4:00p
P/E Ratio
22.49
Dividend Yield
2.82%
Market Cap
$379.01 billion
Rev. per Employee
$603,509
loading...
/zigman2/quotes/205619834/composite
US : U.S.: Nasdaq
$ 70.67
+0.43 +0.61%
Volume: 3.81M
Oct. 27, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$27.72 billion
Rev. per Employee
$177,721
loading...
1 2
This Story has 0 Comments
Be the first to comment
More News In
Economy & Politics

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.